Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Apellis Pharmaceuticals

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Investors Business Daily

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Apellis Pharmaceuticals Stock Shows Rising Relative Strength

A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin

Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.

Investors Business Daily

Markets Today: Stock Indexes Slip as Soaring Crude Prices Spark Inflation Concerns

Morning Markets June S&P 500 futures (ESM2 3) this morning are down -0.18%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.81%. U.S. stock index futures this morning are moderately lower on higher bond yields after the action by OPEC+ to cut its crude production by 1 million...

Barchart

Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval

Apellis Pharmaceuticals snagged FDA approval for the first-ever geographic atrophy treatment, leading APLS stock to surge Tuesday.

Investors Business Daily

Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment

Apellis Pharmaceuticals said Friday the Food and Drug Administration will review its new eye-disease drug in February, and APLS stock surged.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga

Apellis Surges And Breaks Out As FDA Mulls Its Eye-Disease Treatment

The FDA accepted Apellis Pharmaceuticals' application for an eye-disease treatment on Tuesday, leading APLS stock to surge.

Investors Business Daily

Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade

ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.

Investors Business Daily

Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

ApellisPharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 85.

Investors Business Daily

Apellis Begins Paitent Dosing In Late-Stage Study Of Rare Kidney Disease Candidate

Apellis Pharmaceuticals (NASDAQ: APLS) has dosed first patient in the VALIANT Phase 3 clinical study of its drug candidate Pegcetacoplan for primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlyin

Benzinga

Expert Ratings for Apellis Pharmaceuticals

Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know

Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3% over the last 24 hours, at $43.40 per share.

Benzinga

Expert Ratings for Apellis Pharmaceuticals

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter:

Benzinga

Apellis Pharmaceuticals's Earnings: A Preview

Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Apellis Pharmaceuticals will report an earnings per share (EPS) of $-1.32.

Benzinga

Expert Ratings for Apellis Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades

Investors Business Daily

Apellis Pharmaceuticals Stock Shows Rising Relative Strength

ApellisPharmaceuticals sees its Relative Strength Rating move into the elite 90-plus level.

Benzinga

Here's Why Apellis Pharmaceuticals Shares Are Rising

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase 3 Derby and Oaks studies for geographic atrophy.

Benzinga

Expert Ratings For Apellis Pharmaceuticals

Benzinga

Where Apellis Pharmaceuticals Stands With Analysts

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter:

Benzinga

Apellis Pharmaceuticals: Q4 Earnings Insights

Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

Apellis Pharmaceuticals's Earnings Outlook

Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Apellis Pharmaceuticals will report an earnings per share (EPS) of $-1.54.

1 2

Organisations

Food and Drug Administration

US Food and Drug Administration

56 stories

SolarEdge Technologies

52 stories

CoreCivic

51 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Europe

24,892 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.